COMT Val 158 Met polymorphism is associated with cognitive flexibility in a signal discrimination task in schizophrenia [0.03%]
中国精神分裂症患者COMT基因多态性与认知灵活性的相关性研究
A H Neuhaus,C Opgen-Rhein,C Urbanek et al.
A H Neuhaus et al.
Background: Associations between the well-known functional single nucleotide polymorphism Val (158)Met in the gene encoding catechol- O-methyltransferase (COMT) and cognitive do-mains affected in schizophrenia are inconsi...
Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia [0.03%]
精神分裂症门诊治疗中奥氮平剂量调整的原因及转归分析
D Suarez,J M Haro,D Novick et al.
D Suarez et al.
Introduction: Antipsychotic treatment dose adjustments may influence treatment outcomes in patients with schizophrenia. Methods: We ana...
Multicenter Study
Pharmacopsychiatry. 2009 Jul;42(4):135-40. DOI:10.1055/s-0028-1112127 2009
Effects of quetiapine on cognitive functions in schizophrenic patients: a preliminary single-trial ERP analysis [0.03%]
喹硫平对精神分裂症患者认知功能的影响：初步的事件相关电位分析
Y Zhang,M Lehmann,A Shobeiry et al.
Y Zhang et al.
Aim: The study aimed to explore by means of single-trial event-related potentials (ERPs), whether and how the medication change from older neuroleptics to quetiapine in schizophrenic patients led to a significant cognitiv...
Clinical Trial
Pharmacopsychiatry. 2009 Jul;42(4):129-34. DOI:10.1055/s-0028-1112133 2009
Total absence of recall of discussion occurred shortly after ingestion of 10 mg zolpidem [0.03%]
扎 mi 啡诱导的复杂夜间行为伴严重回忆缺损
O Le Bon,D Neu
O Le Bon
Case Reports
Pharmacopsychiatry. 2009 May;42(3):126-7. DOI:10.1055/s-0029-1220772 2009
M Fischera,K Anneken,S Evers et al.
M Fischera et al.
Case Reports
Pharmacopsychiatry. 2009 May;42(3):125-6. DOI:10.1055/s-0028-1112126 2009
C Schönfeldt-Lecuona,R C Wolf,N D Osterfeld et al.
C Schönfeldt-Lecuona et al.
Case Reports
Pharmacopsychiatry. 2009 May;42(3):124-5. DOI:10.1055/s-0028-1112128 2009
M Suda,F Kubota,Y Aihara et al.
M Suda et al.
Case Reports
Pharmacopsychiatry. 2009 May;42(3):122-3. DOI:10.1055/s-0028-1112131 2009
Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study [0.03%]
利培酮治疗不足的 schizophrenic 患者转用艾司西酞普兰的有效性和耐受性：一项多中心开放标签研究
V Ryckmans,J P Kahn,S Modell et al.
V Ryckmans et al.
Introduction: This study evaluated the safety/tolerability and effectiveness of aripiprazole titrated-dose versus fixed-dose switching strategies from risperidone in patients with schizophrenia experiencing insufficient e...
Randomized Controlled Trial
Pharmacopsychiatry. 2009 May;42(3):114-21. DOI:10.1055/s-0028-1112134 2009
Self concept, action control and ADHD symptoms under methylphenidate treatment in adults with ADHD [0.03%]
自我概念、行动控制力以及注意力缺陷多动障碍成人患者在米氮平治疗下的症状表现
M-A Edel,E-M Pfütze,A Lieder et al.
M-A Edel et al.
Introduction: Self-efficacy of adults with ADHD might be changed unfavourably under methylphenidate treatment. Therefore, we sought to investigate the initial situation and changes under this medication, regarding feature...
Psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. Results from the German post-marketing surveillance study [0.03%]
德国上市后监察研究中阿立哌唑治疗的 schizophrenic 患者在门诊环境下的心 理社会功能恢复情况
F Bergmann,A Zacher,A Nass et al.
F Bergmann et al.
Aim: Aripiprazole (ABILIFY) is an effective antipsychotic used in a dose range from 10 to 30 mg, administered once daily. Soon after its approval in Germany for treatment of schizophrenia, a 12-month post-marketing survei...